Damora Therapeutics, Inc.
DMRA
$24.16
$1.074.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.69M | 7.32M | 8.32M | 9.14M | 10.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.56M | 11.88M | 12.57M | 13.76M | 16.90M |
| Operating Income | -36.56M | -11.88M | -12.57M | -13.76M | -16.90M |
| Income Before Tax | -209.79M | -15.85M | -16.59M | -18.45M | -21.40M |
| Income Tax Expenses | 50.00K | -2.00K | 5.00K | 43.00K | 41.00K |
| Earnings from Continuing Operations | -209.84 | -15.84 | -16.59 | -18.50 | -21.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -209.84M | -15.84M | -16.59M | -18.50M | -21.44M |
| EBIT | -36.56M | -11.88M | -12.57M | -13.76M | -16.90M |
| EBITDA | -36.54M | -11.86M | -12.55M | -13.73M | -16.88M |
| EPS Basic | -142.48 | -12.01 | -13.04 | -15.36 | -18.49 |
| Normalized Basic EPS | -15.43 | -5.38 | -6.02 | -6.89 | -8.85 |
| EPS Diluted | -142.48 | -12.01 | -13.04 | -15.36 | -18.49 |
| Normalized Diluted EPS | -15.43 | -5.38 | -6.02 | -6.89 | -8.85 |
| Average Basic Shares Outstanding | 5.45M | 5.29M | 5.10M | 4.87M | 4.63M |
| Average Diluted Shares Outstanding | 5.45M | 5.29M | 5.10M | 4.87M | 4.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |